Establishing structural and functional comparability between ABP 450 and onabotulinumtoxinA to support biosimilarity (AHS 2026) - Jun 11, 2026 - Abstract #T 16; "Integrated genomic, proteomic, and functional analyses demonstrate that ABP 450 and onabotulinumtoxinA share identical primary structures and highly similar biological activity. The absence of structural variants, high peptide coverage, and matched potency profiles collectively support the molecular and functional comparability required for biosimilarity. These findings strengthen the totality of evidence supporting ABP 450 as a biosimilar candidate."
CNS Disorders
|
|
Oh, C.1; Liu, Y.1; Kim, K.2; Too, P.1
|